Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $147.5600 (2.85%) ($143.6100 - $150.1000) on Wed. Jun. 22, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.72% (three month average) | RSI | 51 | Latest Price | $147.5600(2.85%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV advances 1.4% a day on average for past five trading days. | Weekly Trend | ABBV declines -1.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(38%) SPLV(29%) DIA(28%) XLP(28%) VYM(26%) | Factors Impacting ABBV price | ABBV will decline at least -0.86% in a week (0% probabilities). VIXM(-17%) UUP(-14%) TBT(-5%) UNG(-0%) VXX(2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.86% (StdDev 1.72%) | Hourly BBV | 1.3 () | Intraday Trend | 2.7% | | | |
|
1 - 5 Day Possible Target | $136.98(-7.17%) | 5 Day Moving Average | $141.31(4.42%) | 10 Day Moving Average | $142.09(3.85%) | 20 Day Moving Average | $145.1(1.7%) | To recent high | -15.7% | To recent low | 7.2% | Market Cap | $260.338b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |